Synthetic Antibody Mimetics with ROS-Gated Saccharide Release for Targeted Colitis Therapy.

Area of Science:

• Biomaterials Science
• Nanomedicine
• Gastroenterology

Background:

• Conventional targeted therapies for inflammatory bowel disease (IBD) face challenges due to unstable biological recognition elements.
• Molecularly imprinted polymers (MIPs) offer robust synthetic alternatives but suffer from non-specific binding, limiting their efficacy.
• Existing therapies lack precise control over target engagement in inflamed environments.

Purpose of the Study:

• To engineer reactive oxygen species (ROS)-activated therapeutic actuators for IBD treatment.
• To develop a system that overcomes the limitations of static MIPs by enabling controlled, site-specific targeting.
• To create intelligent nanomedicines for enhanced mucosal healing and microbiome modulation in IBD.

Main Methods:

• Conjugating mannose to transferrin-imprinted MIPs via a ROS-cleavable linker to create responsive actuators.
• Utilizing mannose as both a therapeutic agent and a steric shield to prevent non-specific binding during transit.
• Investigating ROS-triggered activation at inflammatory sites for high-affinity epithelial targeting and barrier formation.

Main Results:

• The developed MIPs demonstrated dual functionality: steric blocking of non-specific binding and ROS-activated targeting.
• In murine colitis models, the nanomedicines achieved significant mucosal healing and inflammation mitigation.
• Microbiota rebalancing was observed, with efficacy comparable to free mannose at a dose of 27.2 mg/kg/d.

Conclusions:

• This study presents a generalizable strategy for developing disease-responsive nanomedicines for targeted drug delivery.
• The ROS-activated MIPs offer a promising platform for treating IBD by enabling precise recognition and localized therapeutic action.
• This approach paves the way for intelligent nanomedicines that adapt to complex physiological environments for improved therapeutic outcomes.